M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies Pharmaceutical TechnologyBioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.M&A / DealsImmunology & InflammationRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. M&A / DealsImmunology & InflammationRead full story Post navigation Previous: Medicare obesity drug pilot extended after insurer pushbackNext: BioAegis and Prenosis partner for inflammatory disease therapies Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026